Cancer immunophenotyping by 7 colour multispectral imaging without tyramide signal amplification

Autor: Ijselstein, Marieke, Brouwer, Thomas, Abdulrahman, Ziena, Reidy, Eileen, Ramalheiro, Ana, Heeren, AM, Vahrmeijer, Alexander, Jordanova, ES, de Miranda, Noel

Publikováno v: The Journal of Pathology: Clinical Research, 5(1), 3-11. Wiley-Blackwell Publishing Ltd
Ijselstein, M, Brouwer, T, Abdulrahman, Z, Reidy, E, Ramalheiro, A, Heeren, AM, Vahrmeijer, A, Jordanova, ES & de Miranda, N 2019, ' Cancer immunophenotyping by 7 colour multispectral imaging without tyramide signal amplification ', The Journal of Pathology: Clinical Research, vol. 5, no. 1, pp. 3-11 . https://doi.org/10.1002/cjp2.113

Checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade. Nevertheless, these are only beneficial for a small proportion of cancer patients. Important prognosticators for response to immunotherapy are the mutation b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::24ced3803ab34effc8eb26b026ed5cba
https://research.vumc.nl/en/publications/22bccedf-3cf0-413d-a9c2-6a6dcdb93bfc

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.

Autor: Rotman J; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam University Medical Center (UMC), Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Department of Medical Oncology Amsterdam UMC, Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands., den Otter LAS; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam University Medical Center (UMC), Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Bleeker MCG; Department of Pathology, Cancer Center Amsterdam (CCA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Samuels SS; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam University Medical Center (UMC), Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Heeren AM; Department of Medical Oncology Amsterdam UMC, Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Roemer MGM; Department of Pathology, Cancer Center Amsterdam (CCA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Kenter GG; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam University Medical Center (UMC), Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute-Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Netherlands., Zijlmans HJMAA; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute-Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Netherlands., van Trommel NE; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute-Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Netherlands., de Gruijl TD; Department of Medical Oncology Amsterdam UMC, Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Jordanova ES; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam University Medical Center (UMC), Cancer Center Amsterdam (CCA), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.

Publikováno v: Frontiers in immunology [Front Immunol] 2020 Dec 17; Vol. 11, pp. 596825. Date of Electronic Publication: 2020 Dec 17 (Print Publication: 2020).

Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer.

Autor: Heeren AM; Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, VU University Medical Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, The Netherlands., van Luijk IF; Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, VU University Medical Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Lakeman J; Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, VU University Medical Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Pocorni N; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, The Netherlands., Kole J; Laboratory for Physiology, Institute for Cardiovascular Research, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, The Netherlands., de Menezes RX; Department of Epidemiology and Biostatistics, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, The Netherlands., Kenter GG; Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, VU University Medical Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Bosse T; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., de Kroon CD; Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands., Jordanova ES; Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, VU University Medical Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. e.jordanova@vumc.nl.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Nov; Vol. 68 (11), pp. 1759-1767. Date of Electronic Publication: 2019 Oct 15.

Efficacy of PD-1 blockade in cervical cancer is related to a CD8 ⁺ FoxP3 ⁺ CD25 ⁺ T-cell subset with operational effector functions despite high immune checkpoint levels.

Autor: Heeren AM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Rotman J; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Stam AGM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Pocorni N; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Gassama AA; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Samuels S; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Bleeker MCG; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Mom CH; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Zijlmans HJMAA; Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Kenter GG; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Jordanova ES; Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., de Gruijl TD; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. TD.deGruijl@vumc.nl.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Feb 12; Vol. 7 (1), pp. 43. Date of Electronic Publication: 2019 Feb 12.

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.

Autor: Heeren AM; Center Gynecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, Netherlands.; Cancer Center Amsterdam, Departments of Medical Oncology & Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands., van Dijk I; Cancer Center Amsterdam, Departments of Medical Oncology & Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands., Berry DRAI; Department of Pathology, VU University Medical Center, Amsterdam, Netherlands., Khelil M; Center Gynecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, Netherlands., Ferns D; Center Gynecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, Netherlands., Kole J; Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, Netherlands., Musters RJP; Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, Netherlands., Thijssen VL; Cancer Center Amsterdam, Departments of Medical Oncology & Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands., Mom CH; Center Gynecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam, Netherlands., Kenter GG; Center Gynecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, Netherlands.; Center Gynecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam, Netherlands.; Center Gynecological Oncology Amsterdam (CGOA), Department of Gynecology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands., Bleeker MCG; Department of Pathology, VU University Medical Center, Amsterdam, Netherlands., de Gruijl TD; Cancer Center Amsterdam, Departments of Medical Oncology & Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands., Jordanova ES; Center Gynecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, Netherlands.

Publikováno v: Frontiers in immunology [Front Immunol] 2018 Jul 11; Vol. 9, pp. 1598. Date of Electronic Publication: 2018 Jul 11 (Print Publication: 2018).